Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01289210 · ClinicalTrials.gov registry record · Phase 1
VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas
A Phase 1 study, sponsored by Celgene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 2
- Enrollment target
NCT01289210 is a Phase 1 study that was terminated before completion, run by Celgene. The registered enrollment target is 2 participants.
The verdict
NCT01289210, a Phase 1 study, was terminated before completion, sponsored by Celgene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 2 participants
- Enrollment target
Study Summary
This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.
Interventions
- DRUG VTX-2337 plus radiotherapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2011-07 |
| Est. Completion | 2012-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01289210
The ClinicalTrials.gov registry entry for NCT01289210 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VTX-2337 plus radiotherapy is the first listed.
NCT01289210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01289210 about?
NCT01289210 is a clinical study titled "VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas". This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections ...
What is the current status of trial NCT01289210?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 2 participants. The study started on 2011-07. Estimated completion is 2012-10.
What interventions are being tested in trial NCT01289210?
The interventions under investigation include: VTX-2337 plus radiotherapy (DRUG).
Who is sponsoring clinical trial NCT01289210?
This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.